• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Klaria Pharma Holding AB: Klaria Annual Report 2025

Klaria Pharma Holding
Download the release

Klaria Annual Report 1 January- 31 December 2025

The year in brief

- Net sales amounted to 9.0 MSEK (2.2 MSEK)

- Other operating income amounted to 0.0 MSEK (0.1 MSEK)

- R&D costs amounted to 28.3 MSEK (22.1 MSEK)

- Profit/loss after tax amounted to -47.1 MSEK (-47.8 MSEK)

- Earnings per share amounted to -0.25 SEK (-0.38 SEK)

- Cash flow from operations amounted to -34.2 MSEK (-11.9 MSEK)

- Shareholder's equity as of December 31, 2025 amounted to -12.0 MSEK (3.3 MSEK)

- Cash and cash equivalents as of December 31, 2025 amounted to 0.3 MSEK (0.6 MSEK)